- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
IPCA Labs Quarterly Results 
(IPLB)
Here are the latest quarterly results of IPCA Labs. For more details, see the IPCA Labs financial fact sheet and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA Labs Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-16 |
3
Jun-16 |
3
Sep-16 |
3
Dec-16 |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 6,246 | 8,422 | 8,851 | 7,507 | 6,658 | 7,130 | 8,643 | 8,592 | |
| Other income | Rs m | 87 | 49 | 62 | 59 | 52 | 62 | 110 | 110 | |
| Turnover | Rs m | 6,333 | 8,470 | 8,913 | 7,567 | 6,710 | 7,191 | 8,753 | 8,702 | |
| Expenses | Rs m | 5,639 | 7,218 | 7,492 | 6,443 | 5,981 | 6,914 | 7,153 | 6,980 | |
| Gross profit | Rs m | 526 | 1,204 | 1,358 | 1,065 | 677 | 215 | 1,490 | 1,612 | |
| Depreciation | Rs m | 392 | 422 | 429 | 432 | 428 | 433 | 441 | 438 | |
| Interest | Rs m | 0 | 65 | 68 | 57 | 44 | 56 | 64 | 56 | |
| Profit before tax | Rs m | 221 | 766 | 924 | 636 | 257 | -212 | 1,096 | 1,228 | |
| Tax | Rs m | 156 | 290 | 374 | 222 | -187 | -10 | 131 | 172 | |
| Profit after tax | Rs m | 65 | 476 | 550 | 414 | 444 | -203 | 965 | 1,056 | |
| Gross profit margin | % | 8.4 | 14.3 | 15.3 | 14.2 | 10.2 | 3.0 | 17.2 | 18.8 | |
| Effective tax rate | % | 70.7 | 37.9 | 40.5 | 34.9 | -72.7 | 4.6 | 12.0 | 14.0 | |
| Net profit margin | % | 1.0 | 5.6 | 6.2 | 5.5 | 6.7 | -2.8 | 11.2 | 12.3 | |
| Diluted EPS | Rs | 0.5 | 3.8 | 4.4 | 3.3 | 3.5 | -1.6 | 7.6 | 8.4 | |
| Diluted EPS (TTM) | Rs | 7.6 | 8.9 | 10.5 | 11.9 | 14.9 | 9.5 | 12.8 | 17.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: SUN PHARMA PLETHICO PHARMA MERCK LTD WYETH LTD SHASUN PHARMA
Compare IPCA LABS With: SUN PHARMA PLETHICO PHARMA MERCK LTD WYETH LTD SHASUN PHARMA
Compare IPCA LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)
Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.
Views on news
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)
May 16, 2018The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.
How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)
May 17, 2018A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.
Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)
May 17, 2018Home loans continue to grow, despite falling sales. What explains this phenomenon?
Beware the 5th year of the Modi Regime(The Honest Truth)
May 22, 20182017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...
Beware of Inflated Stock Market Angels(Sector Info)
May 17, 2018The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.
More|
| |
IPCA LABS SHARE PRICE
May 25, 2018 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS 5-YR ANALYSIS
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.